Article
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2017
Horn Leora, Gettinger Scott, Camidge D Ross, Smit Egbert F, Janjigian Yelena Y, Miller Vincent A, Pao William, Freiwald Matthias, Fan Jean, Wang Bushi, Chand Vikram K, Groen Harry J M
Abstract excerpt
OBJECTIVES: In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired resistance to erlotinib or gefitinib. Here, a separate cohort exploring afatinib plus cetuximab after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.